Healthcare -
Medical - Instruments & Supplies - NYSE - US
$ 28.84
-1.21 %
$ 14.8 B
Market Cap
-44.59
P/E
1. INTRINSIC VALUE
Balance Sheet
Baxter International Inc.
| Current Assets | 8.85 B |
| Cash & Short-Term Investments | 1.76 B |
| Receivables | 1.68 B |
| Other Current Assets | 5.41 B |
| Non-Current Assets | 16.9 B |
| Long-Term Investments | 0 |
| PP&E | 3.18 B |
| Other Non-Current Assets | 13.8 B |
| Current Liabilities | 6.51 B |
| Accounts Payable | 968 M |
| Short-Term Debt | 2.75 B |
| Other Current Liabilities | 2.79 B |
| Non-Current Liabilities | 12.2 B |
| Long-Term Debt | 10.6 B |
| Other Non-Current Liabilities | 1.63 B |
EFFICIENCY
Earnings Waterfall
Baxter International Inc.
| Revenue | 4.51 B |
| Cost Of Revenue | 2.81 B |
| Gross Profit | 1.7 B |
| Operating Expenses | 1.38 B |
| Operating Income | -112 M |
| Other Expenses | 214 M |
| Net Income | -326 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Baxter International Inc.
| Net Income | -326 M |
| Depreciation & Amortization | 997 M |
| Capital Expenditures | -446 M |
| Stock-Based Compensation | 114 M |
| Change in Working Capital | -236 M |
| Others | 620 M |
| Free Cash Flow | 559 M |
Wall Street Analysts Price Targets
Baxter International Inc.
Wall Street analysts predict an average 1-year price target for BAX of $39.2 , with forecasts ranging from
a
low of
$30 to a high of $45 .
BAX Lowest Price Target
Wall Street Target
30 USD
4.02%
BAX Average Price Target
Wall Street Target
39.2 USD
35.81%
BAX Highest Price Target
Wall Street Target
45 USD
56.03%
4. DIVIDEND
ANALYSIS
0.99%
DIVIDEND YIELD
0.17 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Baxter International Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery
VIENNA--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of Hemopatch Sealing Hemostat with room temperature storage at a symposium in Austria. The evolution of the product optimizes accessibility in the operating room, delivering an immediate solution for surgeons to control bleeding or prevent leakage. The product is now available to order throughout Europe. “For over a decade, Hemopatch Sealing Hemostat.
businesswire.com
- 3 weeks ago
Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery
VIENNA--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of Hemopatch Sealing Hemostat with room temperature storage at a symposium in Austria. The evolution of the product optimizes accessibility in the operating room, delivering an immediate solution for surgeons to control bleeding or prevent leakage. The product is now available to order throughout Europe. “For over a decade, Hemopatch Sealing Hemostat.
businesswire.com
- 3 weeks ago
Baxter to Host Annual Meeting of Stockholders in Virtual Format
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2025 Annual Meeting) in a virtual format on Tuesday, May 6, 2025 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2025 Annual Meeting. Online access to the 2025 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2025 Annual Meeting in person. The virtual format provides a safe, c.
businesswire.com
- 1 month ago
Baxter Stock Likely to Gain Following the Introduction of Voalte Linq
At the 2025 HIMSS Global Healthcare Conference, BAX unveils its Voalte Linq device, powered by Scotty assistant, a voice-activated technology.
zacks.com
- 1 month ago
Baxter Unveils Voalte Linq Device Powered by Scotty Assistant at HIMSS25 to Advance Voice-Activated Technology in Hospital Settings
LAS VEGAS--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today unveiled Voalte Linq device powered by Scotty assistant, the company's first voice-activated technology, at the 2025 HIMSS Global Healthcare Conference. Voalte Linq, a lightweight, wearable badge, is powered by Scotty assistant, a voice-activated technology, to better enable efficient, streamlined communication between care teams, with the goal of freeing up more of their time and energy to focus on.
businesswire.com
- 1 month ago
Medical Penlight Market Report 2025-2030, with BV Medical, Aspen Surgical Products, Baxter, Streamlight, GF Health Products, Rudolf Riester, American Diagnostic, HONSUN, Prestige Medical & more
Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "Medical Penlight Market Size, Share & Trends Analysis Report By Type (Consumables, Equipment), By Light Output (Oncology, Cardiovascular Diseases), By Usability (Disposable, Reusable), By End-use, By Region, And Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.com's offering. The global medical penlight market size was estimated at USD 279.7 million in 2024 and is projected to grow at a CAGR of 6.6% from 2024 to 2030. The market is driven significantly by the product's utility in diagnosing and assessing eye and ear conditions. According to a WHO report from August 2023, approximately 2.2 billion individuals experience distance vision impairment. Out of this group, vision impairment in at least 1 billion cases could have been prevented or remains untreated. Refractive errors and cataracts are identified as the primary causes of vision impairment and blindness worldwide. Medical professionals rely on penlights for their compact size, ease of use, and focused illumination, which are crucial in conducting detailed examinations of these sensitive areas. In ophthalmology, penlights are indispensable tools for examining the pupils, assessing pupil reactions to light, and detecting abnormalities such as irregularities in pupil size or shape, which can indicate neurological or ocular health issues. They are also crucial in assessing eye movements and conducting basic visual acuity tests, aiding in the diagnosis of conditions such as strabismus or nystagmus. The increasing prevalence of eye and ear disorders, coupled with advancements in penlight technology, is driving market growth. Manufacturers are innovating with features such as LED illumination for brighter and more efficient light output, ergonomic designs for comfortable handling during prolonged use, and enhanced durability for reliability in clinical environments. These advancements not only improve diagnostic accuracy but also streamline workflow efficiency in healthcare settings. In addition, otolaryngology (ENT), medical penlights are used for examining the ear canal, tympanic membrane, and assessing hearing conditions. They help ENT specialists to visualize abnormalities, foreign objects, and signs of infection or inflammation within the ear. Worldwide, the incidence of ENT conditions such as laryngitis, tonsillitis, sinusitis, and hearing loss is increasing. According to the World Health Organization (WHO), over 10% of the global population currently experiences varying degrees of hearing loss, a figure projected to approach nearly 2 billion by 2050. Penlights equipped with otoscopic attachments further enhance their utility by enabling magnified views and facilitating detailed inspections of the ear's internal structures. This capability is crucial for diagnosing conditions such as otitis media, ear wax buildup, and tympanic membrane perforations. Furthermore, the emphasis on preventive healthcare and early diagnosis is further boosting the demand in the medical penlights market. Routine screenings and examinations using penlights help in identifying eye and ear conditions at their early stages, enabling timely interventions and improving patient outcomes. As healthcare facilities continue to prioritize patient care and diagnostic accuracy, the role of medical penlights in supporting comprehensive eye and ear health assessments is expected to expand, driving continued market growth in the coming years. Global Medical Penlight Market Report Segmentation This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, the analyst has segmented the medical penlights market report on the basis of type, light output, usability, end use and region.
globenewswire.com
- 1 month ago
Kontoor Brands CEO Scott Baxter sits down with Jim Cramer
Kontoor Brands Chair, President, and CEO Scott Baxter joins 'Mad Money' host Jim Cramer to talk acquiring Helly Hansen, international business, and more.
youtube.com
- 2 months ago
BAX Stock Surges Following Q4 Earnings & Sales Beat, Margins Decline
Baxter reports better-than-expected fourth-quarter results. However, the company's gross and operating margins contract.
zacks.com
- 2 months ago
Baxter International Inc. (BAX) Q4 2024 Earnings Conference Call Transcript
Baxter International Inc. (BAX) Q4 2024 Earnings Conference Call Transcript
seekingalpha.com
- 2 months ago
Baxter Q4 Earnings Beat Expectations, Issues Strong 2025 Outlook
On Thursday, Baxter International Inc. BAX reported a fourth-quarter 2024 adjusted EPS of 58 cents, beating the management guidance of 50 cents-53 cents and the Wall Street estimate of 52 cents.
benzinga.com
- 2 months ago
Baxter (BAX) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
- 2 months ago
Baxter forecasts 2025 profit above estimates on medical device demand; shares rise
Baxter International on Thursday forecast 2025 profit above Wall Street estimates banking on strong sales of its medical devices, sending the company's shares up 7% in premarket trade.
reuters.com
- 2 months ago
8. Profile
Summary
Baxter International Inc. BAX
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 14.8 B
Dividend Yield
0.99%
Description
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Contact
One Baxter Parkway, Deerfield, IL, 60015
https://www.baxter.com
IPO
Date
Oct. 27, 1981
Employees
38000
Officers
Ms. Anita A. Zielinski
Senior Vice President, Chief Accounting Officer & Controller
Ms. Tobi Karchmer M.D., M.S.
Senior Vice President and Chief Medical & Scientific Officer
Mr. Alok Sonig B.E., Mba
Executive Vice President & Group President of Pharmaceuticals
Ms. Heather Knight
Executive Vice President & Chief Operating Officer
Mr. Jose E. Almeida
Advisor
Mr. David Brent Shafer
Chair & Interim Chief Executive Officer
Mr. Joel T. Grade
Executive Vice President & Chief Financial Officer
Mr. Charles Rusty Patel
Senior Vice President & Chief Information Officer
Ms. Clare Trachtman
Vice President of Investor Relations
Mr. David S. Rosenbloom
Executive Vice President & General Counsel